– Rademikibart demonstrated rapid onset of action with significant improvements in lung function observed at one week and maintained through 24 weeks – – In patients with eosinophilic-driven asthma ...
- First landmark, peer-reviewed publication of successful in vivo CAR T-cell data in an immune competent NHP model -- Data validate the VivoVec™ platform in a translationally relevant model and ...
Immix Biopharma (IMMX) announced the Journal of Clinical Oncology published NXC-201 clinical results in relapsed/refractory AL Amyloidosis. The data reported on 16 enrolled patients in NEXICART-1 who ...
Toronto, Ontario –TheNewswire -13 August 2025–Helix BioPharma Corp. (HBP:CA) (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”)(“Helix”or the ...
BEDMINSTER, N.J., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid ...
RedHill Biopharma (RDHL) announced the new publication of positive in vivo data, in the journal Diabetes, Metabolic Syndrome and Obesity, in an article entitled “Opaganib Promotes Weight Loss and ...
The MarketWatch News Department was not involved in the creation of this content. The NIMML Institute and NImmune Biopharma Announce Publication of New Mechanistic Insights on the Immunometabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results